Generally speaking, small-cap stocks have market capitalizations below $2 billion. They tend to have stronger growth potential over the long run when compared to bigger companies in their respective industries.
Atrion's (ATRI) Q2 EPS drops to 23 cents, down from $3.73 year over year, as merger-related expenses with Nordson hit profits despite strong revenue growth in MPS and fluid delivery segments.
NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Atrion Corporation (NASDAQ: ATRI)'s sale to Nordson Corporation for $460.00 per share in cash. If you are an Atrion shareholder, click here to learn more about your legal rights and options.
| - Industry | - Sector | Mr. David A. Battat CEO | NASDAQ (NGS) Exchange | 049904105 CUSIP |
| DE Country | - Employees | - Last Dividend | 3 Dec 1996 Last Split | - IPO Date |
Atrion Corporation is a diversified company that specializes in the development, manufacture, and sale of a wide range of products primarily designed for fluid delivery, cardiovascular, and ophthalmic applications. Serving a global market, including the United States, Canada, Europe, and internationally, the company caters to the healthcare sector by providing innovative solutions that enhance patient care in the anesthesia, oncology, cardiology, and ophthalmology fields. Founded in 1944 and headquartered in Allen, Texas, Atrion Corporation continues to uphold a commitment to improving health care practices through its extensive product offerings, leveraging direct sales forces, independent sales representatives, and distributors to reach a varied customer base comprising physicians, hospitals, clinics, and treatment centers, as well as other equipment manufacturers.
Atrion's fluid delivery products include advanced valves designed to precisely fill, hold, and release controlled amounts of fluids or gases. These are vital in various medical procedures such as intubation, intravenous therapy, and catheter applications predominantly found in the anesthesia and oncology sectors. Additionally, they play a critical role in promoting infection control within both hospital and home healthcare environments.
The company's cardiovascular product lineup features the Myocardial Protection System (MPS), which is crucial for delivering fluids and medications, mixing critical drugs, and controlling temperature, pressure, and other variables during surgery. Their portfolio also includes cardiac surgery vacuum relief valves, silicone vessel loops for retracting and occluding vessels, inflation devices for balloon catheter dilation and stent deployment, and various products for heart bypass surgery.
Atrion offers a range of balloon catheters designed for the treatment of nasolacrimal duct obstruction in both children and adults. These products are instrumental in ophthalmic applications, providing innovative solutions for common eye conditions.
Besides its mainstay products, Atrion manufactures devices for safe needle and scalpel blade containment, contributing to safer healthcare environments. Their product range also extends to inflation systems and valves for marine and aviation safety, components for inflatable survival products and structures, and one-way and two-way pressure relief valves that protect sensitive electronics and other items during transport, covering both medical and non-medical applications.